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Background: Previous comparative studies have shown similar ef-
ﬁcacy and less toxicity with either, the GV or GD combination respect 
to platinum-based chemotherapies in patients with advanced NSCLC. 
This trial was designed to test the efﬁcacy and safety of both, GV and 
GD combination in non-selected patients with advanced NSCLC. 
Methods: Patients (n=39) with ≤ 75 years old, KPS ≥60% and 
adequate haematological, renal and hepatic function were randomly as-
signed to: G 1250 mg/m2 i.v. d1 and d8 plus either V 25 mg/m 2 i.v. d1 
and d8 or D 35 mg/m 2 i.v. d1 and d8 every 3 weeks. Taxane was given 
over 30 minutes immediately before Gemcitabine, and prophylactic i.v. 
ranitidine (50 mg), diphenhydramine (25 mg) and dexamethasone (8 
mg) were prescribed just prior its administration. 
Results: Baseline characteristics were comparable in GV (n=20) and 
GD (n=19) arms: median age (67 years) and KPS (70%), most of 
patients were male (79%), had metastatic disease (85%) and adenocar-
cinoma histology (55%). Treatment indicated objective response of 7 
(35%) versus 6 (31%) patients, median time-to-treatment failure of 120 
versus 90 days, and overall survival of 209 versus 177 days in GV and 
GD arms respectively. The most common non-haematological toxicities 
were (GV versus GD; no. of patients): grade 2-4 pulmonary toxicity in 
1 versus 7 (37%); grade 2-3 diarrhoea in 0 versus 4 (21%) and oedemas 
1 versus 3. Grade 2-4 haematological toxicities in 5 versus 2 patients. 
All side effects were reversible phenomena since resolution was 
achieved by suspending the treatment and in the case of the pulmonary 
toxicity, by the prescription of additional corticoids. 
Conclusion: The combination of Gemcitabine/Docetaxel does not have 
favourable safety proﬁle with this schedule of administration, par-
ticularly in terms of pulmonary toxicity. Further patients´ accrual was 
stopped and the study has been terminated. This kind of toxicity and 
alternative schedules of GD combination warrants further investigation. 
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Background: The combination of gemcitabine (G) and vinorelbine 
is one of the most effective non-cisplatin based treatment regimens 
for advanced NSCLC. Oral vinorelbine (Ov) has been employed in 
NSCLC treatment with similar bioavailability and response rates and 
a more favourable toxicity proﬁle compared to i.v. form. The GLCG 
conducted a phase II study to determine the efﬁcacy and safety of GOv 
combination in elderly patients with advanced NSCLC. The primary 
objective was response rate (RR) Secondary objectives included time to 
progression (TTP) overall survival (OS) and toxicity.
Methods: 32 chemo-naïve pts histologically conﬁrmed NSCLC, 
aged>70, stage IIIB/IV, ECOG 0/1, measurable lesions according 
RECIST criteria and adecuate bone marrow, renal and hepatic function 
were included. Pts received G 1000 mg/m2/i.v. followed a Ov 60 mg/m2 
(days 1 and 8 every 3 weeeks for a maximum of 6 cycles)
Results: Between July 2005 and January 2007, 32 pts were included 
and 130 cycles were administrated. Male / Female 29/3; median age 
76,8 years (range 70-86), all ECOG 1, 21 squamous cell carcinoma, 9 
adenocarcinoma and 2 large cell. Stage IIIB/IV: 9/23. To date, 26 pts 
were evaluable for response and 30 for toxicity. The RR was 38% (95% 
CI:20-56) PR:38%, SD:27% and PD 35%. The median TTP was 4.5 
months and the median OS was 9 months. The main toxicities were 
anemia grade 3-4 in 4 pts, neutropenia grade 3-4 in 3 and plaquetopenia 
grade 3 in 2; non-haematological grade 3-4 toxicities included grade 3 
asthenia in 3 pts and grade 3 emesis in one pt.
Conclusions: The GOv regimen is effective and well tolerated in 
elderly pts with advanced NSCLC. 
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Background: Nedaplatin (CDGP) is a cisplatin derivative developed 
in Japan. Its response as monotherapy has been reported to be 20.5% 
in non-small cell lung cancer, while when used in combination with 
vindesine (VDS), its efﬁcacy is similar to cisplatin (CDDP). Par-
ticularly in squamous cell carcinoma (SQCC), it is said to achieve 
response rates that are superior to CDDP+VDS. With respect to adverse 
effects, it causes less nausea/vomiting and nephrotoxicity compared to 
CDDP. Since we have used CDGP in combination with the new agent 
docetaxel (TXT) principally for SQCC of the lung, the retrospective 
data to evaluate the efﬁcacy and the safety of this combination are 
reported here.
Methods: Forty patients (male/female 34/6; mean age 65.9 (42-
89) years) with pre-operative (10 IIIA), advanced (IIB/IIIA/IIIB/IV 
2/3/8/11) or recurrent (6) SQCC of the lung with measurable lesions 
and who had previously not been treated with these agents. Thirty 
two patients were chemo-naive, while 8 patients had been previously 
treated with chemotherapy. Thoracic radiation was used separately in 
6 patients. Treatment consisted of 80-140mg/body CDGP and 80-
140mg/body TXT on day one with about 1,000 ml of hydration every 
3-4 weeks. 
Results: Seventy ﬁve cycles were given to 40 patients (mean cycles 
1.88) and the mean dosages actually administered were 66.7 mg/m2 
for CGDP and 65.4 mg/m2 for TXT. An over all response rate was 
55.0% (2 CR, 20 PR, 11 NC, 1 PD). The mean survival time was 17.2 
months and the survival rate was 63.0% at 1 year, 37.8% at 2 years, 
and 33.1% at 3 years. Thirty patients without resection after treatment 
(24 advanced and 6 recurrent cases) had a mean survival time of 14.6 
months and a survival rate of 53.7% at 1 year, 20.7% at 2 years, and 
10.3% at 3 years. NCI-CTC grades 3-4 neutropenia, thrombocytopenia, 
nausea/vomiting occurred in 50 (66.7%), 2 (2.7%), 2 (2.7%) cycles, 
respectively. There was no grade 3-4 anemia and nephrotoxicity .
Conclusions: We conclude that a combination of CDGP and TXT has 
adequate tolerability, gives high response rates, and thus is a useful 
therapy for advanced or recurrent squamous cell carcinomas in lung.
